AU707476B2 - Lactoferrin variants and uses thereof - Google Patents

Lactoferrin variants and uses thereof Download PDF

Info

Publication number
AU707476B2
AU707476B2 AU32271/97A AU3227197A AU707476B2 AU 707476 B2 AU707476 B2 AU 707476B2 AU 32271/97 A AU32271/97 A AU 32271/97A AU 3227197 A AU3227197 A AU 3227197A AU 707476 B2 AU707476 B2 AU 707476B2
Authority
AU
Australia
Prior art keywords
lactoferrin
iron
eukaryotic cell
vector
iron binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU32271/97A
Other languages
English (en)
Other versions
AU3227197A (en
Inventor
Orla M. Conneely
Pauline P. Ward
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baylor College of Medicine
Original Assignee
Baylor College of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor College of Medicine filed Critical Baylor College of Medicine
Publication of AU3227197A publication Critical patent/AU3227197A/en
Application granted granted Critical
Publication of AU707476B2 publication Critical patent/AU707476B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU32271/97A 1996-05-31 1997-06-02 Lactoferrin variants and uses thereof Ceased AU707476B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US1874796P 1996-05-31 1996-05-31
US60/018747 1996-05-31
US08/866544 1997-05-30
US08/866,544 US6111081A (en) 1996-05-31 1997-05-30 Lactoferrin variants and uses thereof
PCT/US1997/009531 WO1997045136A1 (en) 1996-05-31 1997-06-02 Lactoferrin variants and uses thereof

Publications (2)

Publication Number Publication Date
AU3227197A AU3227197A (en) 1998-01-05
AU707476B2 true AU707476B2 (en) 1999-07-08

Family

ID=26691448

Family Applications (1)

Application Number Title Priority Date Filing Date
AU32271/97A Ceased AU707476B2 (en) 1996-05-31 1997-06-02 Lactoferrin variants and uses thereof

Country Status (12)

Country Link
US (1) US6111081A (enExample)
EP (1) EP0959898A4 (enExample)
JP (1) JP2000511424A (enExample)
KR (1) KR20000016159A (enExample)
AU (1) AU707476B2 (enExample)
CA (1) CA2256453A1 (enExample)
DE (1) DE959898T1 (enExample)
ES (1) ES2140362T1 (enExample)
GR (1) GR990300043T1 (enExample)
IL (1) IL127319A (enExample)
NZ (1) NZ333215A (enExample)
WO (1) WO1997045136A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU747385C (en) * 1997-04-10 2003-01-30 Agennix, Inc. Use of lactoferin in the treatment of allergen induced disorders

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL94183A (en) * 1989-05-05 2003-09-17 Baylor College Medicine cDNA SEQUENCE CODING FOR HUMAN LACTOFERRIN PROTEIN OR PORTION THEREOF AND LACTOFERRIN PROTEIN PRODUCED FROM SAID SEQUENCE
JP2002515893A (ja) * 1997-02-03 2002-05-28 ファーミング インテレクチュアル プロパティ ビーブイ ヒトラクトフェリンおよびその改変体の有用な特性
US6399570B1 (en) 1999-02-05 2002-06-04 Agennix, Inc. Antimicrobial/endotoxin neutralizing polypeptide
JP3668241B2 (ja) * 2001-12-28 2005-07-06 株式会社Ｎｒｌファーマ 脂質代謝改善用組成物
US20030213007A1 (en) * 2002-03-27 2003-11-13 Slattery Charles Wilbur Human milk produced by human mammary tissue implanted in non-human host animals and uses thereof
EP2286827A1 (en) 2002-05-10 2011-02-23 Agennix Incorporated Lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases
AU2003233583A1 (en) * 2002-05-24 2003-12-12 Agennix Incorporated Oral lactoferrin in the treatment of respiratory disorders
DK2298338T3 (da) * 2002-09-16 2012-09-24 Agennix Inc Lactoferrin-sammensætninger og fremgangsmåder til behandling af hudsår
JP4795021B2 (ja) * 2002-12-06 2011-10-19 エイジェニックス インコーポレイテッド 敗血症治療における経口用ラクトフェリン
US7592306B2 (en) * 2002-12-10 2009-09-22 Agennix, Inc. Lactoferrin as an agent in the prevention of organ transplant rejection and graft-versus-host-disease
WO2004060392A1 (en) * 2002-12-20 2004-07-22 Ventria Bioscience Lactoferrin protein with iron for treating iron deficiency and anemia
AU2004289170B2 (en) * 2003-06-06 2009-12-17 Agennix Incorporated Lactoferrin as an adjuvant in cancer vaccines
US20040259770A1 (en) * 2003-06-19 2004-12-23 Rush University Medical Center Method for determining leukocyte activation
US20050075277A1 (en) * 2003-07-10 2005-04-07 Agennix Incorporated Use of lactoferrin in prophylaxis against infection and/or inflammation in immunosuppressed subjects
WO2006047744A2 (en) * 2004-10-26 2006-05-04 Agennix Incorporated Compositions of lactoferrin related peptides and uses thereof
NZ555163A (en) 2007-05-14 2010-05-28 Fonterra Co Operative Group Methods of immune or hematological enhancement, inhibiting tumour formation or growth, and treating or preventing cancer, cancer symptoms, or the symptoms of cancer treatments
RU2340674C1 (ru) * 2007-06-01 2008-12-10 Борис Савельевич Народицкий Способ получения рекомбинантного лактоферрина человека
JP5855239B2 (ja) * 2012-04-23 2016-02-09 株式会社Ｎｒｌファーマ ラクトフェリン融合タンパク質及びその製造方法
EP3533870A4 (en) 2016-10-28 2020-04-08 NRL Pharma, Inc. LACTOFERRIN / ALBUMIN FUSION PROTEIN AND PROCESS FOR PRODUCING THE SAME
WO2020096672A1 (en) 2018-11-09 2020-05-14 The Wistar Institute Of Anatomy And Biology Use of lactoferrin for generating myeloid-derived suppressor cells

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5186117A (en) * 1975-01-27 1976-07-28 Tanabe Seiyaku Co Johoseibiryushiseizainoseiho
GB1575343A (en) * 1977-05-10 1980-09-17 Ici Ltd Method for preparing liposome compositions containing biologically active compounds
US4529561A (en) * 1978-03-24 1985-07-16 The Regents Of The University Of California Method for producing liposomes in selected size range
IN150740B (enExample) * 1978-11-24 1982-12-04 Hoffmann La Roche
GB2046092B (en) * 1979-03-05 1983-11-02 Toyama Chemical Co Ltd Pharmaceutical composition containing a lysophospholid and a phospholipid
US4634665A (en) * 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4394443A (en) * 1980-12-18 1983-07-19 Yale University Method for cloning genes
US4452747A (en) * 1982-03-22 1984-06-05 Klaus Gersonde Method of and arrangement for producing lipid vesicles
US4766075A (en) * 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
US4652639A (en) * 1982-05-06 1987-03-24 Amgen Manufacture and expression of structural genes
US4725442A (en) * 1983-06-17 1988-02-16 Haynes Duncan H Microdroplets of water-insoluble drugs and injectable formulations containing same
US4703008A (en) * 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
US4740461A (en) * 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US4710465A (en) * 1984-04-19 1987-12-01 Yale University Junction-fragment DNA probes and probe clusters
US5008050A (en) * 1984-06-20 1991-04-16 The Liposome Company, Inc. Extrusion technique for producing unilamellar vesicles
LU85479A1 (fr) * 1984-07-25 1986-02-12 Oleofina Sa Compositions antibacteriennes de nourriture pour animaux et procede pour les preparer
US4921706A (en) * 1984-11-20 1990-05-01 Massachusetts Institute Of Technology Unilamellar lipid vesicles and method for their formation
JPS61145200A (ja) * 1984-12-19 1986-07-02 Snow Brand Milk Prod Co Ltd ウシラクトフェリンの分離精製法
US4886747A (en) * 1985-03-22 1989-12-12 Genentech, Inc. Nucleic acid encoding TGF-β and its uses
AU5912586A (en) * 1985-06-20 1986-12-24 Salk Institute Biotechnology/Industrial Associates, Inc., The Alpha-factor leader peptide-facilitated secretion from transformed s cerevisiae
FR2583676B1 (fr) * 1985-06-24 1988-03-25 Induplast Sa Procede et appareils d'extrusion de structures alveolaires en matiere thermoplastique et structures ainsi obtenues
US4959318A (en) * 1985-06-27 1990-09-25 Zymogenetics, Inc. Expression of protein C
US4800159A (en) * 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US4737323A (en) * 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
US4965190A (en) * 1986-07-31 1990-10-23 Howard Hughes Medical Institute Methods for the identification of mutations in the human phenylalanine hydroxylase gene using DNA probes
US4920016A (en) * 1986-12-24 1990-04-24 Linear Technology, Inc. Liposomes with enhanced circulation time
US5009956A (en) * 1987-02-24 1991-04-23 Univ Minnesota Phospholipase A2-resistant liposomes
US5019508A (en) * 1987-08-27 1991-05-28 Biotechnology Research Partners, Ltd. Synovial phospholipases
DE3886221T3 (de) * 1987-09-04 2000-12-21 Novo Nordisk A/S, Bagsvaerd VERFAHREN ZUR HERSTELLUNG VON PROTEINPRODUKTEN IN -i(ASPERGILLUS) UND PROMOTOREN ZUR VERWENDUNG IN -i(ASPERGILLUS).
US5081227A (en) * 1988-03-04 1992-01-14 La Jolla Cancer Research Foundation Germ cell alkaline phosphatase
US4927637A (en) * 1989-01-17 1990-05-22 Liposome Technology, Inc. Liposome extrusion method
US4944948A (en) * 1989-02-24 1990-07-31 Liposome Technology, Inc. EGF/Liposome gel composition and method
US5571691A (en) * 1989-05-05 1996-11-05 Baylor College Of Medicine Production of recombinant lactoferrin and lactoferrin polypeptides using CDNA sequences in various organisms
US5571697A (en) * 1989-05-05 1996-11-05 Baylor College Of Medicine Texas Medical Center Expression of processed recombinant lactoferrin and lactoferrin polypeptide fragments from a fusion product in Aspergillus
US5155037A (en) * 1989-08-04 1992-10-13 The Texas A&M University System Insect signal sequences useful to improve the efficiency of processing and secretion of foreign genes in insect systems
IL95697A0 (en) * 1989-09-28 1991-06-30 Granada Biosciences Inc Cdna sequence for porcine lactoferrin protein
AU7453391A (en) * 1990-03-08 1991-10-10 Ferrodynamics, Inc. Genetically engineered human lactoferrin
JP2818056B2 (ja) * 1990-09-07 1998-10-30 森永乳業株式会社 抗菌性ペプチドおよび抗菌剤
US5166145A (en) * 1990-09-10 1992-11-24 Alza Corporation Antiemetic therapy
NZ245713A (en) * 1992-02-10 1994-12-22 Novopharm Ltd Production of the antibiotic lovastatin from genetically engineered aspergillus strains
ZA932568B (en) * 1992-04-24 1993-11-12 Baylor College Midecine A Non Production of recombinant human lactoferrin
US5571619A (en) * 1994-05-24 1996-11-05 Exxon Chemical Patents, Inc. Fibers and oriented films of polypropylene higher α-olefin copolymers

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DAY ETAL. J.BIOL.CHEM. 1992, 267(20):13857-13862 *
TWEEDIE ETAL FROM LAC.:STRUC.&FUNC. ED H.ETAL NY'94 P197-208 *
WARD ETAL. GENE. 1992, 122:219-223 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU747385C (en) * 1997-04-10 2003-01-30 Agennix, Inc. Use of lactoferin in the treatment of allergen induced disorders

Also Published As

Publication number Publication date
AU3227197A (en) 1998-01-05
US6111081A (en) 2000-08-29
NZ333215A (en) 2000-05-26
JP2000511424A (ja) 2000-09-05
KR20000016159A (ko) 2000-03-25
GR990300043T1 (en) 2000-01-31
ES2140362T1 (es) 2000-03-01
CA2256453A1 (en) 1997-12-04
EP0959898A4 (en) 2002-08-14
WO1997045136A1 (en) 1997-12-04
EP0959898A1 (en) 1999-12-01
DE959898T1 (de) 2000-05-04
IL127319A0 (en) 1999-09-22
IL127319A (en) 2004-08-31

Similar Documents

Publication Publication Date Title
US6111081A (en) Lactoferrin variants and uses thereof
WO1997045136A9 (en) Lactoferrin variants and uses thereof
KR100393508B1 (ko) 인간 인터루킨 4의 안타고니스트 또는 부분적 아고니스트로서의 신규hIL-4 변이단백질
EP0375724B1 (en) Biologically active bactericidal/permeability-increasing protein fragments
DE69431654T2 (de) Antimikrobielles peptid aus rinderneutrophilen
US5948408A (en) DNA encoding bactericidal/permeability-increasing proteins
KR100631766B1 (ko) 폴리펩티드, 그 폴리펩티드를 암호화하는 ｃＤＮＡ 및그들의 용도
US6376462B1 (en) Lipopolysaccharide binding protein derivatives
JPH07502490A (ja) 殺菌性／透過性増大タンパク質および脂質担体を含有する組成物、その製造方法、およびそれらの使用
US7985832B2 (en) Antimicrobial cathelicidin peptides
JP2003528827A (ja) カゼイン由来ペプチドおよびその医療用途
US5851986A (en) Promoting bone formation and inhibiting bone resorption with high mobility group protein-1 (HMG-1)
EP0337799B1 (en) 14-Beta-gal mammalian lectins
JP2011503137A (ja) 新規のアルギニン置換ペプチド及びその使用
JP2002516339A (ja) ＬＡＩＴ／ｓＣＤ１４−蛋白質による抗生物質蛋白質およびペプチドの誘導
HU210694B (en) Method for production of new cell growth regulatory factor
MXPA98010080A (en) Variants of lactoferrina and uses of the mi
US5770561A (en) Method for potentiating BPI protein product bactericidal activity by administration of LBP protein products
WO2000008056A1 (fr) NOUVEAU POLYPEPTIDE, ADNc LE CODANT ET SON UTILISATION
EP0628631A1 (en) A phosphatidylethanolamine binding protein derived from a human glioblastoma cell line and DNA encoding it
Ul Haq Casoxins
HK1021333A (en) Lactoferrin variants and uses thereof
JPS638398A (ja) 生理活性ポリペプチド
JP3534434B2 (ja) トロンボモジュリン類発現用シグナルペプチド
MX2010010795A (es) Uso de defensinas contra meningitis.